BioCentury | May 2, 2013
Tools & Techniques

CTCs gain character(ization)

Despite the recent shuttering of circulating tumor cell diagnostic company On-Q-ity Inc. , researchers at Massachusetts General Hospital think there is still reason to innovate in the space. The group has developed a microfluidic platform able...
BioCentury | Apr 15, 2013
Company News

Johns Hopkins University other research news

Johns Hopkins School of Medicine researchers published in Science the use of SAGE to compare expressed genes in normal and cancerous cells. About 60,000 sequence tags were obtained from each of normal colon cells, colon...
BioCentury | Dec 7, 2009
Company News

Asterand, Bristol-Myers deal

...deal, originally between Bristol-Myers and Pharmagene plc, was previously extended and expanded in 2004 and 2007. Pharmagene...
BioCentury | May 21, 2007
Company News

Asterand, Bristol-Myers deal

...studies for BMY (see BioCentury, Jan. 5, 2004). BMY struck the original deal and with Pharmagene plc...
BioCentury | Feb 27, 2006
Company News

Argenta Discovery management update

...Ltd.; Chris Moyses as CMO and a director, formerly R&D director and executive director at Pharmagene plc...
BioCentury | Feb 6, 2006
Company News

Asterand, BTG deal

...royalties. ATD was formed last September through the merger of Asterand Inc. (Detroit, Mich.) and Pharmagene plc...
BioCentury | Jan 30, 2006
Company News

S*BIO Pte Ltd. management update

...Hired: Stephen Rhind as SVP of business development, formerly VP of business development at Pharmagene plc's Pharmagene...
BioCentury | Sep 26, 2005
Company News

Asterand Inc., Pharmagene deal

...and had $3.2 million in cash at Dec. 31, 2004. Asterand Inc. , Detroit, Mich. Pharmagene plc...
BioCentury | Sep 19, 2005
Company News

Pharmagene exits drug development

Pharmagene (LSE:PGN) announced a 50-50 stock merger with Asterand (Detroit, Mich.) and said it will discontinue its therapeutics operations. The combined company, to be called Asterand plc , will trade on the London Stock Exchange and...
BioCentury | May 26, 2005
Company News

Paradigm names Riddell CEO

...is deputy chairman of the U.K.'s Biotechnology Industry Association (BIA) and previously was CEO of Pharmagene...
Items per page:
1 - 10 of 138
BioCentury | May 2, 2013
Tools & Techniques

CTCs gain character(ization)

Despite the recent shuttering of circulating tumor cell diagnostic company On-Q-ity Inc. , researchers at Massachusetts General Hospital think there is still reason to innovate in the space. The group has developed a microfluidic platform able...
BioCentury | Apr 15, 2013
Company News

Johns Hopkins University other research news

Johns Hopkins School of Medicine researchers published in Science the use of SAGE to compare expressed genes in normal and cancerous cells. About 60,000 sequence tags were obtained from each of normal colon cells, colon...
BioCentury | Dec 7, 2009
Company News

Asterand, Bristol-Myers deal

...deal, originally between Bristol-Myers and Pharmagene plc, was previously extended and expanded in 2004 and 2007. Pharmagene...
BioCentury | May 21, 2007
Company News

Asterand, Bristol-Myers deal

...studies for BMY (see BioCentury, Jan. 5, 2004). BMY struck the original deal and with Pharmagene plc...
BioCentury | Feb 27, 2006
Company News

Argenta Discovery management update

...Ltd.; Chris Moyses as CMO and a director, formerly R&D director and executive director at Pharmagene plc...
BioCentury | Feb 6, 2006
Company News

Asterand, BTG deal

...royalties. ATD was formed last September through the merger of Asterand Inc. (Detroit, Mich.) and Pharmagene plc...
BioCentury | Jan 30, 2006
Company News

S*BIO Pte Ltd. management update

...Hired: Stephen Rhind as SVP of business development, formerly VP of business development at Pharmagene plc's Pharmagene...
BioCentury | Sep 26, 2005
Company News

Asterand Inc., Pharmagene deal

...and had $3.2 million in cash at Dec. 31, 2004. Asterand Inc. , Detroit, Mich. Pharmagene plc...
BioCentury | Sep 19, 2005
Company News

Pharmagene exits drug development

Pharmagene (LSE:PGN) announced a 50-50 stock merger with Asterand (Detroit, Mich.) and said it will discontinue its therapeutics operations. The combined company, to be called Asterand plc , will trade on the London Stock Exchange and...
BioCentury | May 26, 2005
Company News

Paradigm names Riddell CEO

...is deputy chairman of the U.K.'s Biotechnology Industry Association (BIA) and previously was CEO of Pharmagene...
Items per page:
1 - 10 of 138